Menu Close

Bristol-Myers Squibb Company’s Stock Gains 5.07%, But It May Still Be Worth Investing In.

The trading price of Bristol-Myers Squibb Company (NYSE:BMY) floating higher at last check on Friday, September 09, closing at $73.72, 5.07% higher than its previous close.

Traders who pay close attention to intraday price movement should know that it has been fluctuating between $69.22 and $70.5469. The company’s P/E ratio in the trailing 12-month period was 23.32, while its 5Y monthly beta was 0.44. In examining the 52-week price action we see that the stock hit a 52-week high of $80.59 and a 52-week low of $53.22. Over the past month, the stock has lost -6.28% in value.

Lithium Stocks In The Spotlight

Here’s a company — undiscovered by Wall Street and trading below $0.30 per share — which just recently uncovered 8 high-quality targets on unexplored ground, and drills will be turning later this year. Very few investors know about it yet… so the ground-floor opportunity below $0.30 won’t be around much longer. It’s a brand new breed of lithium explorer — all you need to do is click and the name and trading symbol is yours.

It’s all in the FREE report you can get here. .

Sponsored

Bristol-Myers Squibb Company, whose market valuation is $148.14 billion at the time of this writing, is expected to release its quarterly earnings report Apr 27, 2022 – May 02, 2022. The dividend yield on the company stock is 3.08%, while its Forward Dividend ratio is 2.16. Investors’ optimism about the company’s current quarter earnings report is understandable. Analysts have predicted the quarterly earnings per share to grow by $1.85 per share this quarter, however they have predicted annual earnings per share of $7.51 for 2022 and $8.02 for 2023. It means analysts are expecting annual earnings per share growth of 6.80% next year.

Analysts have forecast the company to bring in revenue of $11.19 billion for the current quarter, with the likely lows of $10.81 billion and highs of $11.63 billion. The average estimate suggests sales will likely down by -3.40% this quarter compared to what was recorded in the comparable quarter last year. From the analysts’ viewpoint, the consensus estimate for the company’s annual revenue in 2022 is $46.12 billion. The company’s revenue is forecast to drop by -0.60% over what it did in 2022.

A company’s earnings reviews provide a brief indication of a stock’s direction in the short term, where in the case of Bristol-Myers Squibb Company No upward and no downward comments were posted in the last 7 days. On the technical side, indicators suggest BMY has a Hold on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a Hold, while an average of long term indicators suggests that the stock is currently 50% Buy.

Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned BMY a recommendation rating is 21. Out of them, 7 rate it a Hold, while 11 recommend Buy, whereas 1 assign an Overweight rating. 1 analyst(s) have tagged Bristol-Myers Squibb Company (BMY) as Underweight, while 1 advise Sell. Analysts have rated the stock Overweight, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.

If we dig deeper into the stock’s outlook, we see that the stock’s PEG is 5.14, which symbolizes a positive outlook. A quick review shows that BMY’s price is currently 3.34% off the SMA20 and 0.83% off the SMA50. The RSI metric on the 14-day chart is currently showing 58.95, and weekly volatility stands at 1.89%. When measured over the past 30 days, the indicator reaches 2.03%. Bristol-Myers Squibb Company (NYSE:BMY)’s beta value is currently sitting at 0.42, while the Average True Range indicator is currently displaying 1.46. With analysts defining $61.00-$94.00 as the low and high price targets, we arrive at a consensus price target of $81.53 for the trailing 12-month period. The current price is about 17.25% off the estimated low and -27.51% off the forecast high, based on this estimate. Investors will be thrilled if BMY’s share price rises to $84.00, which is the median consensus price. At that level, BMY’s share price would be -13.94% below current price.

To see how Bristol-Myers Squibb Company stock has been performing today in comparison to its peers in the industry, here are the numbers: BMY stock’s performance was 5.07% at last check in today’s session, and 10.35% in the past year, while Johnson & Johnson (JNJ) has been trading 0.10% in recent session and positioned -1.40% lower than it was a year ago. Another comparable company Pfizer Inc. (PFE) saw its stock trading 0.68% higher in today’s session but was up 3.93% in a year. Furthermore, Abbott Laboratories (ABT) showed an increase of 0.89% today while its price kept declining at -15.24% over the past year. Bristol-Myers Squibb Company has a P/E ratio of 23.32, compared to Johnson & Johnson’s 24.09 and Pfizer Inc.’s 9.22. Also during today’s trading, the S&P 500 Index has surged 0.95%, while the Dow Jones Industrial also saw a positive session, up 0.87% today.

An evaluation of the daily trading volume of Bristol-Myers Squibb Company (NYSE:BMY) indicates that the 3-month average is 10.13 million. However, this figure has increased over the past 10 days to an average of 9.97 million.

Currently, records show that 2.14 billion of the company’s shares remain outstanding. The insiders hold 0.10% of outstanding shares, whereas institutions hold 79.80%. The stats also highlight that short interest as of Jul 14, 2022, stood at 27.33 million shares, resulting in a short ratio of 2.25 at that time. From this, we can conclude that short interest is 1.28% of the company’s total outstanding shares. It is noteworthy that short shares in July were down slightly from the previous month’s figure, which was 34.46 million. However, since the stock’s price has seen 12.53% year-to-date, investors’ interest is likely to be reignited due to its potential to move even higher.